OTCMKTS:IGXT IntelGenx Technologies - IGXT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $0.16 -0.01 (-5.80%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.16▼$0.1750-Day Range$0.16▼$0.2652-Week Range$0.11▼$0.37Volume6,210 shsAverage Volume104,747 shsMarket Capitalization$28.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About IntelGenx Technologies (OTCMKTS:IGXT) StockIntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. Its products include rizaport, tadalafil, loxapine, and montelukast. The company also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research & development, clinical monitoring, regulatory support, tech transfer & manufacturing scale-up and commercial manufacturing. IntelGenx Technologies was founded on July 27, 1999 and is headquartered in Ville Saint-Laurent, Canada.Read More Receive IGXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address IGXT Stock News HeadlinesFebruary 21, 2023 | finance.yahoo.comIntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible PatentFebruary 9, 2023 | finance.yahoo.comIntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s DiseaseMarch 20, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …January 23, 2023 | finance.yahoo.comIntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA CountriesDecember 7, 2022 | finance.yahoo.comIntelGenx Announces Collaboration with UPEI to Evaluate Acceptance and Preference of VetaFilm™ Platform in Dogs and CatsNovember 22, 2022 | finance.yahoo.comIntelGenx Receives FDA PDUFA Date for RIZAFILM®November 18, 2022 | seekingalpha.comIntelGenx Technologies Corp. (IGXT) Q3 2022 - Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comIntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast VendorMarch 20, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.November 3, 2022 | markets.businessinsider.comNew Oral Film Tech Improving Cannabinoid Onset Seeks Patent ProtectionNovember 3, 2022 | finance.yahoo.comIntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to FollowNovember 2, 2022 | finance.yahoo.comIntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of ActionOctober 25, 2022 | msn.comCanadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA TrackOctober 25, 2022 | finance.yahoo.comIntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal FilmOctober 13, 2022 | finance.yahoo.comIntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug CandidateOctober 4, 2022 | msn.comShort Volatility Alert: IntelGenx Technologies Corp.July 29, 2022 | theglobeandmail.comIntelgenx Technologies Corp WT stock $verbed on Wednesday.July 29, 2022 | theglobeandmail.comIntelgenx Technologies Corp WT stock $verbed on Thursday.July 5, 2022 | finance.yahoo.comIntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on DebenturesMay 12, 2022 | finance.yahoo.comIntelGenx Reports First Quarter 2022 Financial ResultsMarch 26, 2022 | seekingalpha.comIntelGenx slumps 10% after fourth quarter's resultsMarch 23, 2022 | msn.comPsychedelic Stock Gainers And Losers From March 23, 2022March 9, 2022 | msn.comPsychedelic Stock Gainers And Losers From March 9, 2022March 8, 2022 | msn.comPsychedelic Stock Gainers And Losers From March 8, 2022March 7, 2022 | msn.comPsychedelic Stock Gainers And Losers From March 7, 2022February 1, 2022 | finance.yahoo.comIntelGenx Receives Third Loan Tranche from ataiJanuary 20, 2022 | msn.comPsychedelic Stock Gainers And Losers From January 18, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IGXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address IGXT Company Calendar Last Earnings11/12/2020Today3/20/2023Next Earnings (Estimated)3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IGXT CUSIP45822R101 CIK1098880 Webwww.intelgenx.com Phone(514) 331-7440Fax514-331-0436Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,320,000.00 Net Margins-850.04% Pretax Margin-850.28% Return on Equity-863.97% Return on Assets-70.29% Debt Debt-to-Equity Ratio5.92 Current Ratio2.59 Quick Ratio2.56 Sales & Book Value Annual Sales$1.53 million Price / Sales18.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book5.41Miscellaneous Outstanding Shares174,650,000Free Float91,235,000Market Cap$28.35 million OptionableNot Optionable Beta2.48 Key ExecutivesHorst G. ZerbeChairman & Chief Executive OfficerAndré GodinPresident & Chief Financial OfficerRodolphe ObeidChief Operating OfficerNadine PaiementVice President-Research & DevelopmentDana MatzenVice President-Business & Corporate DevelopmentKey CompetitorsTFF PharmaceuticalsNASDAQ:TFFPSatsuma PharmaceuticalsNASDAQ:STSAHelix BioPharmaOTCMKTS:HBPCFSELLAS Life Sciences GroupNASDAQ:SLSLumos PharmaNASDAQ:LUMOView All Competitors IGXT Stock - Frequently Asked Questions How have IGXT shares performed in 2023? IntelGenx Technologies' stock was trading at $0.1973 at the start of the year. Since then, IGXT stock has decreased by 17.7% and is now trading at $0.1623. View the best growth stocks for 2023 here. Are investors shorting IntelGenx Technologies? IntelGenx Technologies saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 5,800 shares, an increase of 93.3% from the February 13th total of 3,000 shares. Based on an average trading volume of 214,700 shares, the days-to-cover ratio is presently 0.0 days. View IntelGenx Technologies' Short Interest. When is IntelGenx Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our IGXT earnings forecast. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01. The company earned $0.51 million during the quarter. IntelGenx Technologies had a negative trailing twelve-month return on equity of 863.97% and a negative net margin of 850.04%. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), Zevra Therapeutics (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL), Ampio Pharmaceuticals (AMPE), BioDelivery Sciences International (BDSI), BIOLASE (BIOL) and Ocugen (OCGN). What is IntelGenx Technologies' stock symbol? IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT." How do I buy shares of IntelGenx Technologies? Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IntelGenx Technologies' stock price today? One share of IGXT stock can currently be purchased for approximately $0.16. How much money does IntelGenx Technologies make? IntelGenx Technologies (OTCMKTS:IGXT) has a market capitalization of $28.35 million and generates $1.53 million in revenue each year. The company earns $-9,320,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. How can I contact IntelGenx Technologies? IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The official website for the company is www.intelgenx.com. The company can be reached via phone at (514) 331-7440, via email at stephen@intelgenx.com, or via fax at 514-331-0436. This page (OTCMKTS:IGXT) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.